CORONA Remedies Limited (NSE:CORONA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Pharmaceuticals	11.96B	10.14B	8.84B	6.17B
Pharmaceuticals Growth	17.93%	14.75%	43.21%	-
Total	11.96B	10.14B	8.84B	6.17B
Total Growth	17.93%	14.75%	43.21%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India	11.52B	9.80B	8.52B	5.95B
India Growth	17.57%	15.03%	43.19%	-
outside India	439.59M	342.46M	318.89M	221.88M
outside India Growth	28.36%	7.39%	43.72%	-
Total	11.96B	10.14B	8.84B	6.17B
Total Growth	17.93%	14.75%	43.21%	-

Source: S&P Global Market Intelligence.